Janus Henderson Group
OBIO icon

Janus Henderson Group’s Orchestra BioMed OBIO Stock Holding History

Janus Henderson Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-74,049
Closed -$758K – 2215
2021
Q2 		$758K Buy
74,049
+1,244
+2% +$12.9K ﹤0.01% 1365
2021
Q1 		$815K Sell
72,805
-97,471
-57% -$1.19M ﹤0.01% 1288
2020
Q4 		$2.18M Sell
170,276
-10,495
-6% -$120K ﹤0.01% 1109
2020
Q3 		$2M Buy
+180,771
New +$2.03M ﹤0.01% 1058

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group's OBIO Position: Q3 2021 in Review

Janus Henderson Group sold out of Orchestra BioMed (OBIO) in Q3 2021, closing a stake of 74,049 shares — an estimated $758K sold.

Janus Henderson Group first reported a position in OBIO in Q3 2020 and held it in 4 quarters. The position peaked at $2.18M in Q4 2020. 48 funds tracked by Wall St. Rank hold OBIO as of Q3 2021.

  • Janus Henderson Group reported no remaining Orchestra BioMed position as of Q3 2021 after selling out during the quarter.
  • Janus Henderson Group sold 74,049 Orchestra BioMed shares in Q3 2021, an estimated $758K.
  • Janus Henderson Group first reported a position in Orchestra BioMed in Q3 2020 and held it in 4 quarters.
  • Janus Henderson Group's Orchestra BioMed position peaked at $2.18M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2021.

Based on Janus Henderson Group's 13F filing for Q3 2021, filed 16 Nov 2021.